Literature DB >> 27074060

Homoleptic versus Heteroleptic Formation of Mononuclear Fe(II) Complexes with Tris-Imine Ligands.

Leoní A Barrios1, Carlos Bartual-Murgui1,2, Eugènia Peyrecave-Lleixà1, Boris Le Guennic3, Simon J Teat4, Olivier Roubeau2, Guillem Aromí1.   

Abstract

We show a marked tendency of Fe(II) to form heteroleptic [Fe(L)(L')](ClO4)2 complexes from pairs of chelating tris-imine 3bpp, tpy, or 2bbp ligands. New synthetic avenues for spin crossover research become thus available, here illustrated with three new heteroleptic compounds with differing magnetic behaviors: [Fe(H4L1)(Cl-tpy)](ClO4)2·C3H6O (1), [Fe(H2L3)(Me3bpp)](ClO4)2·C3H6O (2), [Fe(H4L1)(2bbp)](ClO4)2·3C3H6O (3). Structural studies demonstrate that 1 is in the low-spin (LS) state up to 350 K, while complexes 2 and 3 are, by contrast, in the high-spin (HS) state down to 2 K, as corroborated through magnetic susceptibility measurements. Upon exposure to the atmosphere, the latter exhibits the release of three molecules of acetone per complex, turning into the solvent-free analogue [Fe(H4L1)(2bbp)](ClO4)2 (3a), through a single-crystal-to-single-crystal transformation. This guest extrusion process is accompanied by a spin switch, from HS to LS.

Entities:  

Year:  2016        PMID: 27074060     DOI: 10.1021/acs.inorgchem.5b02058

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  2 in total

1.  Room-Temperature Spin Crossover in a Solution of Iron(II) Complexes with N,N'-Disubstituted Bis(pyrazol-3-yl)pyridines.

Authors:  Dmitry Yu Aleshin; Igor Nikovskiy; Valentin V Novikov; Alexander V Polezhaev; Elizaveta K Melnikova; Yulia V Nelyubina
Journal:  ACS Omega       Date:  2021-11-22

2.  Reversible guest-induced gate-opening with multiplex spin crossover responses in two-dimensional Hofmann clathrates.

Authors:  Rubén Turo-Cortés; Carlos Bartual-Murgui; Javier Castells-Gil; M Carmen Muñoz; Carlos Martí-Gastaldo; José Antonio Real
Journal:  Chem Sci       Date:  2020-09-22       Impact factor: 9.825

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.